Global Duchenne Muscular Dystrophy Therapeutics Market Primary and Secondary Research, Segmentation, Projections, SWOT Analysis and Forecast by 2022

OrbisResearch.com has published new research report on "Global Duchenne Muscular Dystrophy Therapeutics Market By Drug (Translarna, Emflaza, EXONDYS 51), By Therapeutic Approach (Steroid Therapy, Exon Skipping, Mutation Suppression) Forecast to 2022" to its database.

Dallas, United States - July 17, 2017 /MarketersMedia/ —

Duchenne Muscular Dystrophy (DMD) is a fatal genetic disorders diagnosed in children around the world. DMD is often referred to as orphan or rare diseases, as it affects only a small portion of the population, approximately 1 in every 3,500 live male births. However, various treatment approaches are available now-a-days that can inhibit progression of the disease. Amongst, the most attractive are molecular based therapies, such as mutation suppression or exon skipping. Moreover, there are many more drugs in various phases of clinical trials, which will help in the growth of this market.

Browse the report: http://www.orbisresearch.com/reports/index/global-duchenne-muscular-dystrophy-therapeutics-market-by-drug-translarna-emflaza-exondys-51-by-therapeutic-approach-steroid-therapy-exon-skipping-mutation-suppression-forecast-to-2022

According to RNCOS’ new research report “Global Duchenne Muscular Dystrophy Therapeutics Market By Drug (Translarna, Emflaza, EXONDYS 51), By Therapeutic Approach (Steroid Therapy, Exon Skipping, Mutation Suppression) Forecast to 2022”, the Duchenne Muscular Dystrophy Therapeutics industry can possibly turn into a multi-million dollar industry by the end of 2022, as new products, particularly those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth.

The Duchenne Muscular Dystrophy Therapeutics market has very few marketed products, such as Emflaza, Translarna, and EXONDYS 51. The market is majorly in the research phase, from which most of its revenue is generated. Therefore, a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the Duchenne Muscular Dystrophy market, such as phases, geographies, etc. The report also provides the sales of major marketed Duchenne Muscular Dystrophy products, and the list of the products in clinical/pre-clinical research along with their clinical phases.

Request a sample of the report: http://www.orbisresearch.com/contacts/request-sample/333580

The report provides a detailed analysis of the current and future market scenario of the global Duchenne Muscular Dystrophy Therapeutics market. RNCOS, in its report, further covers insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global Duchenne Muscular Dystrophy Therapeutics market. The report also provides insights regarding the strategies adopted by the players from 2015 to 2017 for enhancing their market share.
The segmentation of Duchenne Muscular Dystrophy Therapeutics market has been done on the basis of different therapeutic approaches and geographical regions. Primarily, the Duchenne Muscular Dystrophy Therapeutics market is dominated by mutation suppression and exon skipping approach, with several companies and academic institutions focusing on potential for each of these treatments.

Based on the geography, the market is divided into three regions, namely - North America, Europe, and Asia Pacific. There are several treatments for DMD that are approved or under review in the European Union or are expected to be under review by regulatory agencies in the near future. This is a major reason for the dominant position of Europe in the Duchenne Muscular Dystrophy market.

Buy the report@http://www.orbisresearch.com/contact/purchase/333580

The later part of the report discusses some of the prominent players in the global Duchenne Muscular Dystrophy Therapeutics market. The market share analysis of these players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their business segments, product portfolios and recent developments. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.

Major Points From The Table Of Contents:
Analyst View
Research Methodology
Duchenne Muscular Dystrophy (DMD): An Overview
Market Dynamics
Global Duchenne Muscular Dystrophy Therapeutics Market Outlook 2022
Approved Drugs
Market Segmentation by Therapeutic Approach
Market Segmentation by Geography
Clinical Trial Assessment & Pipeline Analysis
Industry Trends and Developments
Strategic Alliances
Competitive Landscape
Key Player Analysis

List of Figures:
Figure 5-1: Global - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022
Figure 6-1: Global - Sales of EXONDYS 51 (Million US$), 2016
Figure 6-2: Global - Sales of Translarna (Million US$), 2014-2017
Figure 7-1: Global - Duchenne Muscular Dystrophy Therapeutics Market by Therapeutic Approach (%), 2016
Figure 7-2: Global - Mutation Suppression Market for Duchenne Muscular Dystrophy (Million US$), 2016-2022
Figure 7-3: Global - Steroid Therapy Market for Duchenne Muscular Dystrophy (Million US$), 2016-2022
Figure 7-4: Global - Exon Skipping Therapy Market for Duchenne Muscular Dystrophy (Million US$), 2016-2022
Figure 8-1: Global - Duchenne Muscular Dystrophy Therapeutics Market by Geography (%), 2016
Figure 8-2: Europe - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022
Figure 8-3: North America - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022
Figure 8-4: Asia Pacific - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022

List of Tables:
Table 4-1: Grants for Duchenne Muscular Dystrophy
Table 4-2: Per-Patient Annual Costs of DMD, 2012
Table 6-1: Ongoing Trials for Emflaza
Table 6-2: Ongoing Trials for EXONDYS 51
Table 6-3: Ongoing Trials for Translarna
Table 7-1: Disease-Modifying Therapies for Duchenne Muscular Dystrophy
Table 9-1: Global Duchenne Muscular Dystrophy Therapeutics Pipeline

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Info:
Name: Hector Costello
Email: sales@orbisresearch.com
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600, Dallas, Texas – 75204, U.S.A.
Phone: +1 (214) 884-6817

Source URL: http://marketersmedia.com/global-duchenne-muscular-dystrophy-therapeutics-market-primary-and-secondary-research-segmentation-projections-swot-analysis-and-forecast-by-2022/217967

For more information, please visit http://www.orbisresearch.com/reports/index/global-duchenne-muscular-dystrophy-therapeutics-market-by-drug-translarna-emflaza-exondys-51-by-therapeutic-approach-steroid-therapy-exon-skipping-mutation-suppression-forecast-to-2022

Source: MarketersMedia

Release ID: 217967

Latest News

Gunmen kill 2 polio workers in Pakistan, mother and daughter

Jan 19, 2018

QUETTA, Pakistan — Gunmen shot and killed a mother and her daughter who were working for an anti-polio campaign underway in Pakistan's southwestern city of Quetta on Thursday, police said. The attack took place as hundreds of polio teams were vaccinating children against the crippling disease, police official Naseeb Ullah said. Pakistan this week launched a drive against polio across the country. In a separate attack in Quetta, the capital of Baluchistan province, assailants killed two policemen. Prime Minister Shahid Khaqan Abbasi condemned the attacks. There was no immediate claim of responsibility for either attack. Pakistan, Afghanistan and Nigeria are...

Pakistan launches new anti-polio drive in Punjab province

Jan 19, 2018

LAHORE, Pakistan — A Pakistani health official says a special anti-polio drive has been launched in the country's eastern Punjab province. Imran Nazir says the week-long campaign was launched on Monday amid tight security. He says thousands of workers are taking part in the drive by going house-to-house to vaccinate children in the struggle to eradicate the crippling disease. Pakistan, Afghanistan and Nigeria are the only three countries left in the world where polio has not been eliminated. Pakistan regularly launches anti-polio drives despite threats from the Taliban who perceive the campaign as part of a Western conspiracy and claim...

Iran oil tanker explodes, sinks off China with no survivors

Jan 19, 2018

TEHRAN, Iran — A burning Iranian oil tanker exploded and sank Sunday after more than a week listing off the coast of China, as an Iranian official acknowledged there was "no hope" of missing sailors surviving the disaster. The collision and disaster of the Sanchi, which carried 30 Iranians and two Bangladeshis, had transfixed an Iran still reeling from days of protests and unrest that swept the country at the start of the year. Families of the sailors wept and screamed at the headquarters of the National Iranian Tanker Co. in Tehran, the private company that owns the Sanchi. Some...

Aid group projects 48,000 births in crowded Rohingya camps

Jan 19, 2018

DHAKA, Bangladesh — An aid agency projects 48,000 babies will be born this year in the refugee camps for Rohingya Muslims who have fled to Bangladesh after military operations against them in Myanmar. The babies will probably be born in tents in unsanitary conditions and will be at increased risk of disease and malnutrition, and of dying before age 5, Save the Children warned in its report Friday. "The camps have poor sanitation and are a breeding ground for diseases like diphtheria, measles and cholera, to which newborn babies are particularly vulnerable," said Rachael Cummings, the agency's health adviser in...

India's new 'driverless' metro train keeps driver for now

Jan 19, 2018

NEW DELHI — India's capital launched a metro train with driverless technology Monday, though officials said it would operate with a driver for at least a year or two. Prime Minister Narendra Modi took an inaugural ride on a short section of the 12.6-kilometer (7.8-mile) Magenta Line, which connects the southern part of New Delhi with the satellite city of Noida, an IT hub across the Yamuna river. The Delhi Metro Rail Corp. has said the highly automated train will run initially with a driver but could become driverless in the future. An official told the Indian Express newspaper that...

Sign up now!

Recent Discovery will take you to the captivating developments in science, technology, and the universe around us. We deliver to you the latest news, theories, and developments in the world of science.

Contact us: sales@recentdiscovery.com